Promore’s Enserpetide Has Phase II Setback In Scar Prevention, Focus Shifts To Ropocamptide

The Swedish firm’s lead program has unexpectedly disappointed in a Phase II scar prevention trial, prompting it to turn its efforts to its only other clinical asset for the treatment of chronic wounds.